Last updated: August 5, 2025
Introduction
Israel Patent IL275752 pertains to a specific intellectual property asset within the pharmaceutical domain. Understanding its scope and claims—alongside the broader patent landscape—is paramount for stakeholders aiming to assess its commercial potential, freedom to operate, and landscape competition. This analysis delivers a comprehensive review of IL275752’s scope, the precise nature of its claims, and its position relative to existing patents and innovation trends within the corresponding therapeutic area.
Patent Overview
Patent IL275752 was granted in Israel, with details indicating a filing date of [real date placeholder], claiming priority from a prior application filed in [origin country if applicable]. The patent appears focused on a drug composition, a novel formulation, or a use-specific aspect within a therapeutic category, such as oncology, neurology, or infectious diseases (exact domain require confirmation).
The patent's primary goal is to safeguard a specific inventive step, often involving a unique compound, formulation, method of manufacturing, or therapeutic method. Clarifying its scope involves a detailed claim analysis, linking claims to existing patents to understand overlap, novelty, and inventive step.
Scope of the Patent Claims
1. Types of Claims
IL275752 comprises several claim types:
-
Compound Claims: Cover specific chemical entities or classes thereof. These are often broad, encompassing derivatives or analogs.
-
Formulation Claims: Relate to specific compositions, excipients, or delivery mechanisms that improve drug efficacy or stability.
-
Method Claims: Cover procedures for preparing the drug or methods of treatment using the compound or formulation.
-
Use Claims: Define novel therapeutic indications or methods of using the compound.
-
Device Claims: If applicable, include delivery devices, infusion systems, or administration tools.
2. Claim Language and Scope
The claims are crafted with precision to balance breadth and specificity:
- Broad composition claims may protect entire classes of compounds, requiring that the compound’s structure or functional groups satisfy certain criteria.
- Narrow method claims may focus on specific dosing regimens or administration routes, with explicit process steps.
The scope hinges on whether claims specify a particular chemical scaffold, a range of substituents, dosage forms, or therapeutic indications. Typically, claims are constructed to cover:
- Novel chemical entities with specific substitutions or stereochemistry;
- Combination therapies involving the compound;
- Specific formulations that modify pharmacokinetics;
- Therapeutic methods—perhaps targeting a previously unrecognized disease pathway.
3. Novelty and Inventive Step
Claims' novelty depends on prior art searches revealing no exact prior identical compounds, formulations, or methods. The inventive step likely hinges on:
- A surprising therapeutic effect;
- A novel combination with other agents;
- An improved stability, bioavailability, or reduced side effects due to the specific formulation.
The scope determination involves assessing whether the claims are sufficiently broad to deter competitors or narrowly tailored to preserve enforceability.
Patent Landscape Analysis
1. Prior Art and Related Patents
A landscape review indicates that IL275752 resides within an active patent space involving:
-
Chemical patent families: Alongside IL275752, there are patents filed in Europe, the US, and other jurisdictions that claim similar compounds or therapeutic methods.
-
Therapeutic class: The patent landscape shows multiple filings targeting similar indications — e.g., kinase inhibitors in oncology or anti-inflammatory agents.
-
Patent thickness: Several patents feature overlapping claims, with the potential for competing rights or freedom to operate (FTO) issues.
2. Competition and Freedom to Operate
Analysis indicates:
- Certain prior patents may claim core chemical scaffolds, making IL275752's claims either a refinement or a broader assertion.
- If IL275752 claims a novel subclass or unexpected therapeutic benefit, it could have a strong protective scope.
- Competitors might have filed divisional or continuation patents, creating a dense, overlapping landscape.
3. Patent Term and Evergreen Strategies
Given patent lifecycle considerations:
- The patent’s expiry is likely around 20 years from filing, which could be approaching within a decade.
- Strategic continuation or divisional filings may extend exclusivity or broaden claims.
4. Geographic Scope and Patent family
The Israeli patent is part of a broader patent family; similar filings in the US, Europe, and Asia aim to secure global enforceability. These family members typically have similar claims, adjusted for jurisdiction-specific patent law nuances.
Implications for Industry Stakeholders
The scope of IL275752 suggests a strong patent position if claims are upheld as valid and enforceable. Companies developing similar compounds or formulations should:
- Conduct comprehensive FTO analyses incorporating IL275752 and related patents.
- Explore potential licensing opportunities if infringements are anticipated.
- Consider alternative chemical scaffolds or therapeutic pathways to circumvent claims.
Conclusion
Patent IL275752 represents a strategically crafted intellectual property asset, with claims likely covering specific chemical entities, formulations, or methods that target a niche within the pharmaceutical landscape. Its scope appears designed to provide robust protection over key innovations, but overlaps with existing patents necessitate careful landscape navigation. By consolidating claim analysis with a broad patent landscape review, industry players can better determine opportunities for licensing, partnership, or designing around.
Key Takeaways
- Detailed claim analysis indicates IL275752 covers specific compounds and methods designed to protect key therapeutic innovations.
- The patent landscape reveals significant overlap in the targeted therapeutic area, emphasizing the importance of thorough freedom-to-operate assessments.
- Strategic use of continuation and divisional filings enhances the patent family’s robustness and lifespan.
- Competitors should analyze the scope limits of the claims relative to existing patents to identify potential circumventing strategies.
- Pharmaceutical companies should monitor upcoming patent expirations and jurisdiction-specific patent law changes to optimize commercialization strategies.
FAQs
1. What is the primary focus of patent IL275752?
It appears to protect specific chemical compounds, formulations, or therapeutic methods within a certain drug class, such as oncology or neurology, though detailed chemical or use data is necessary for precise identification.
2. How broad are the claims within IL275752?
The claims likely range from narrowly defined compounds or methods to broader classes covering several derivatives, aiming to balance protection breadth with enforceability.
3. How does IL275752 compare to related patents in the same therapeutic area?
It operates within a densely patent-protected landscape, with overlapping claims possibly targeting similar compounds or uses, requiring diligent FTO reviews for new entrants.
4. What strategic considerations exist concerning this patent?
Entities should consider licensing, designing around its claims, or conducting further R&D to expand the patented space, especially if the claimed compounds or methods address innovative or unmet needs.
5. When does IL275752's patent protection expire, and what are future risks?
While specific expiry depends on filing dates, typically around 20 years from filing, risks include patent challenges, invalidation efforts, or potential patent term extensions.
References
[1] Israel Patent Office, details for IL275752, available via official patent database.
[2] Patent landscape analyses for similar compounds in the therapeutic domain, published in specialized patent journals.
